Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Receivables - Net (2016 - 2022)

Historic Receivables - Net for Summit Therapeutics (SMMT) over the last 5 years, with Q4 2022 value amounting to $349000.0.

  • Summit Therapeutics' Receivables - Net fell 7616.12% to $349000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $349000.0, marking a year-over-year decrease of 7616.12%. This contributed to the annual value of $349000.0 for FY2022, which is 7616.12% down from last year.
  • As of Q4 2022, Summit Therapeutics' Receivables - Net stood at $349000.0, which was down 7616.12% from $140000.0 recorded in Q3 2022.
  • In the past 5 years, Summit Therapeutics' Receivables - Net ranged from a high of $17.3 million in Q1 2019 and a low of $140000.0 during Q3 2022
  • For the 4-year period, Summit Therapeutics' Receivables - Net averaged around $5.5 million, with its median value being $1.9 million (2021).
  • Per our database at Business Quant, Summit Therapeutics' Receivables - Net crashed by 9682.8% in 2020 and then soared by 34229.61% in 2021.
  • Quarter analysis of 4 years shows Summit Therapeutics' Receivables - Net stood at $10.4 million in 2019, then tumbled by 96.83% to $331000.0 in 2020, then skyrocketed by 342.3% to $1.5 million in 2021, then crashed by 76.16% to $349000.0 in 2022.
  • Its Receivables - Net was $349000.0 in Q4 2022, compared to $140000.0 in Q3 2022 and $238000.0 in Q2 2022.